---
schema_version: "secwatch.filing_event.v1"
accession: "0001827506-24-000032"
form_type: "8-K"
ticker: null
cik: "0001827506"
company_name: "Tourmaline Bio, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:39:07.089576+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tourmaline Bio Q1 2024 net loss $13.3M; cash $350.3M; Phase 2 TRANQUILITY initiated

## Summary
- Net loss $13.3M ($0.55 basic/diluted loss per share) for Q1 2024, compared to $7.5M ($8.28) in Q1 2023.
- Cash, cash equivalents and investments $350.3M as of March 31, 2024, providing cash runway into 2027.
- Initiated Phase 2 TRANQUILITY trial in ASCVD/CKD in April 2024; topline data expected in H1 2025.
- Plans to initiate pivotal Phase 3 trial for TOUR006 in TED in H2 2024; Phase 2b spiriTED topline in 2025.
- Completed $172.5M follow-on offering in January 2024, net proceeds $161.3M.

## SEC filing metadata
- accession: 0001827506-24-000032
- form_type: 8-K
- cik: 0001827506
- company_name: Tourmaline Bio, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/0001827506-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/trml-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827506-24-000032
- JSON: https://secwatch.observer/filing/0001827506-24-000032.json
- Plain text: https://secwatch.observer/filing/0001827506-24-000032.txt

## Key facts
- Earnings Releases
  Tourmaline Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $13.3 million for the first quarter of 2024 and $7.5 million for the first quarter of 2023, resulting in ba.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss was $13.3 million for the first quarter of 2024 and $7.5 million for the first quarter of 2023, resulting in ba
  - Result: reported results
  source text: On May 13, 2024, Tourmaline Bio, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/0001827506-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.